Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - dulaglutiidi - suhkurtõbi, tüüp 2 - drugs used in diabetes, blood glucose lowering drugs, excl. insulins - trulicity is indicated for the treatment of patients 10 years and above with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance or contraindicationsin addition to other medicinal products for the treatment of diabetes. uuringu tulemused seoses kombinatsioonid, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

novartis europharm limited - vildagliptiin - suhkurtõbi, tüüp 2 - dipeptidyl peptidase 4 (dpp-4) inhibitors, drugs used in diabetes - vildagliptin is indicated as an adjunct to diet and exercise to improve glycaemic control in adults with type 2 diabetes mellitus:as monotherapy in patients in whom metformin is inappropriate due to contraindications or intolerance. in combination with other medicinal products for the treatment of diabetes, including insulin, when these do not provide adequate glycaemic control (see sections 4. 4, 4. 5 ja 5. 1 erinevate kombinatsioonide kohta kättesaadavate andmete osas).

Euroopa Liit - eesti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propaandiool monohüdraat, metformiin vesinikkloriid - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - tüüp 2 diabeet mellitusfor ravi piisavalt kontrollitud tüüp 2 diabeet lisandina, et toitumine ja treening. kui monotherapy kui metformiin on ebasobivaks, kuna sallimatuse. lisaks teiste ravimitega ravi 2. tüüpi diabeedi. uuringu tulemused seoses kombinatsiooni teraapia, mõju glycaemic kontrolli ja kardiovaskulaarsete sündmuste ja elanikkonna uuritud, vt punktid 4. 4, 4. 5 ja 5. 1. tüüpi diabeet mellitusedistride on näidustatud täiskasvanute raviks, kui ebapiisavalt kontrollitud tüüp 1 diabeet lisandina, et insuliiniga patsientidel, kelle kmi on ≥ 27 kg/m2, kui insuliiniga üksi ei anna adekvaatset glycaemic kontrolli hoolimata optimaalset insuliini ravi.

Euroopa Liit - eesti - EMA (European Medicines Agency)

glaxosmithkline (ireland) limited - dostarlimab - endometrial neoplasms - antineoplastic agents and antibody drug conjugates - jemparli is indicated as monotherapy for the treatment of adult patients with mismatch repair deficient (dmmr)/microsatellite instability-high (msi h) recurrent or advanced endometrial cancer (ec) that has progressed on or following prior treatment with a platinum-containing regimen.

Euroopa Liit - eesti - EMA (European Medicines Agency)

mirum pharmaceuticals international b.v. - maralixibat chloride - alagille syndrome - other drugs for bile therapy - livmarli is indicated for the treatment of cholestatic pruritus in patients with alagille syndrome (algs) 2 months of age and older.

Euroopa Liit - eesti - EMA (European Medicines Agency)

pfizer europe ma eeig  - voxelotor - anemia; anemia, hemolytic; anemia, sickle cell - other hematological agents - oxbryta is indicated for the treatment of haemolytic anaemia due to sickle cell disease (scd) in adults and paediatric patients 12 years of age and older as monotherapy or in combination with hydroxycarbamide.

Euroopa Liit - eesti - EMA (European Medicines Agency)

merck sharp & dohme b.v. - ertugliflozin l-pyroglutamic happega - suhkurtõbi, tüüp 2 - drugs used in diabetes, sodium-glucose co-transporter 2 (sglt2) inhibitors - steglatro on näidustatud täiskasvanutel vanuses 18 aastat ja vanemad, tüüp 2 diabeet lisandina toitumise ja treeningu parandamiseks glycaemic kontroll:kui monotherapy patsientidel, kellele kasutamise metformiin on ebasobivaks, kuna talumatus või vastunäidustused. lisaks teiste ravimitega ravi diabeet.

Euroopa Liit - eesti - EMA (European Medicines Agency)

eli lilly nederland b.v. - tirzepatide - suhkurtõbi, tüüp 2 - diabeetis kasutatavad ravimid - mounjaro is indicated for the treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise- as monotherapy when metformin is considered inappropriate due to intolerance or contraindications- in addition to other medicinal products for the treatment of diabetes. for study results with respect to combinations, effects on glycaemic control and the populations studied, see sections 4. 4, 4. 5 ja 5.

Euroopa Liit - eesti - EMA (European Medicines Agency)

nanotherapeutics bohumil, s.r.o. - whole virion influenza vaccine, inactivated containing antigen of strain a/california/07/2009 (h1n1)v - disease outbreaks; influenza, human; immunization - vaktsiinid - a (h1n1) v 2009 viirusega põhjustatud gripi profülaktika. celvapan tuleks kasutada vastavalt euroopa liidu arendus.

Euroopa Liit - eesti - EMA (European Medicines Agency)

takeda pharma a/s - brigatinib - kartsinoom, mitteväikerakk-kopsu - antineoplastilised ained - alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase (alk)‑positive advanced non‑small cell lung cancer (nsclc) previously not treated with an alk inhibitor. alunbrig is indicated as monotherapy for the treatment of adult patients with anaplastic lymphoma kinase alkpositive advanced nsclc previously treated with crizotinib.